Introduction Beijing VDJ BioCo., Ltd. was established in July 2011 and is committed to the independent research and development of innovative monoclonal antibody drugs. It has independently developed the world's leading core technology - the antibody affinity enhancement and high-throughput screening platform that mimics the antibody maturation mechanism in the human body. |